1. Home
  2. BFLY
  3. Earnings

AI Earnings Predictions for Butterfly Network Inc. (BFLY)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-2.54%

$7.22

0% positive prob.

5-Day Prediction

-9.77%

$6.68

0% positive prob.

20-Day Prediction

-9.46%

$6.70

0% positive prob.

Price at prediction: $7.41 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -2.54% -9.77% -9.46% 100.0% Pending
Q2 2026 SELL -2.68% -9.77% -9.55% 100.0% +1.59%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Oct 29, 2026 · 100% conf.

AI Prediction SELL

1D

-2.54%

$7.22

Act: -17.54%

5D

-9.77%

$6.68

20D

-9.46%

$6.70

Price: $7.41 Prob +5D: 0% AUC: 1.000
0001804176-26-000038

EX-99.1

2 bfly-20261029xexx991.htm

EX-99.1

Document

Exhibit 99.1

Butterfly Network Reports Third Quarter 2026 Financial Results

Beats High End of Quarterly Revenue and Adjusted EBITDA Guidance

•Delivered quarterly Revenue of $32.6 million, driven in part by Embedded revenue

•Recorded highest gross margin in Company history at 73%

•Management increases Full Year Revenue and Adjusted EBITDA Guidance

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “Our third quarter results came in ahead of guidance on both revenue and adjusted EBITDA, and we posted the highest gross margin in Butterfly’s history. We saw strength across our business. The enterprise pipeline is turning into signed deals, and achieving FedRAMP authorization puts larger federal opportunities on the table. Home & Community Care has also moved from building the program to executing it, with first revenue expected this November.”

DeVivo continued, “What excites me most is that our progress is compounding as we laid out. Our Ultrasound-on-Chip™ platform is taking Butterfly into entirely new categories, from brain-computer interfaces to physical AI. The first Embedded partner product is now on the market, and we have next-generation technology in motion. Every step forward expands the markets we can serve, and more than a decade of investment in this semiconductor platform is beginning to deliver on the vast potential we have expected.”

Recent Operational and Strategic Highlights:

•Butterfly Embedded™: Added three BCI partners, including the announcements of Merge Labs and Bridge Neurotech in the third quarter, while Mendaera became the first partner to launch a commercial product built on Butterfly technology on October 1, 2026.

•Compass AI™ and Enterprise Momentum: Closed five 7-figure and ten 6-figure TCV enterprise deals in the quarter.

•FedRAMP: Officially achieved FedRAMP authorization as expected, supporting federal and VA pipeline opportunities.

•Medical Education: Announced the Lighthouse program with VCOM, a multi-year partnership to equip every VCOM student with a Butterfly device and generate insights on POCUS use from medical school into residency.

•Butterfly Garden™: Signed five new partners, and DeepEcho became the first international and first maternal health partner application to go live on October 23, 2026.

•Home & Community Care: Entered the implementation phase to launch the first state, with scanning set to begin in November and initial revenue expected in the fourth quarter.

•International Expansion: Built momentum in Brazil, and added a new distribution partner in Taiwan.

•Innovation Roadmap: Advanced development of the Apollo chip on schedule; prepared a limited release of wearable research devices for Embedded partners; and continue preparations to launch a next-generation product powered by the P5.1 chip in early 2027.

Three Months Ended September 30, 2026 Financial Results

Revenue: Total revenue was $32.6 million, representing growth of 52% from $21.5 million in the third quarter of 2025. U.S. revenue was $27.5 million, up 71% from prior year, primarily driven by revenue from our various Butterfly Embedded™ partnerships, including our co-development partnership with Midjourney, as well as increased probe sales volume to our health system, distributor, and eCommerce customers. International revenue decreased 5% year-over-year to $5.1 million, largely resulting from decreased probe sales to our global health partners.

Gross margin: Gross profit was $23.8 million versus a gross loss of $3.8 million in the prior year period, and adjusted gross profit was $23.8 million versus $13.7 million in the prior year period. Total gross margin, on a GAAP basis, was 73.0% compared to (17.5)% in the prior year period, and adjusted gross margin increased to 73.0% from 63.9% in the prior year period. The $27.6 million increase in GAAP gross margin is due in part to the $17.4 million write-down of excess and obsolete inventory that was recognized during the prior year period, which is excluded from adjusted gross profit and adjusted gross margin. The remainder of the increase in GAAP gross margin, as well as the $10.1 million increase in adjusted gross margin, was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as our increased probe sales volume in the current year.

Operating expenses: Operating expenses were $37.4 million, up 19% from $31.4 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses wer

2026
Q2

Q2 2026 Earnings

8-K SELL

Jul 30, 2026 · 100% conf.

AI Prediction SELL

1D

-2.68%

$7.95

Act: -12.97%

5D

-9.77%

$7.37

Act: +1.59%

20D

-9.55%

$7.39

Price: $8.17 Prob +5D: 0% AUC: 1.000
0001804176-26-000025

EX-99.1

2 bfly-20260730xexx991.htm

EX-99.1

Document

Exhibit 99.1

Butterfly Network Reports Second Quarter 2026 Financial Results

Delivered Record Revenue and Adjusted EBITDA Loss Above Guidance

•Raised full year Revenue and Improved Adjusted EBITDA Guidance

•Delivered quarterly Revenue of $32.6 million in Q2, representing 39% YoY growth

•Delivered 71% Gross Margin, up 770 bps

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.

Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "Butterfly delivered another outstanding quarter, exceeding the high end of our guidance while achieving record revenue, gross margin and adjusted EBITDA. Just as important, the world got to see what Ultrasound-on-Chip™ is capable of as two Embedded partners unveiled entirely new applications being built on our platform. It's an exciting milestone for Butterfly and a validation of the opportunity we've believed in for years."

DeVivo continued, "As those announcements captured global attention, they also highlighted something bigger: Butterfly has evolved into a multi-engine growth company. Our semiconductor platform is expanding into new markets through Butterfly Embedded; our POCUS business is building a larger enterprise opportunity through software, medical education and government; and Home & Community Care is transitioning from pilot to commercialization. Together, these growth engines reinforce one another and continue to expand our long-term opportunity."

Recent Operational and Strategic Highlights:

•Butterfly Embedded™: Added two new partners to the Embedded portfolio, totaling 11 partners, with Midjourney and Aleph Neuro unveiling the groundbreaking applications they’re building with Butterfly's Ultrasound-on-Chip™ platform.

•Compass AI™ and Enterprise Momentum: Signed six new enterprise software agreements and expanded the Compass AI software pipeline meaningfully year over year.

•FedRAMP Progress: Received provisional authorization to sell across the U.S. Department of Veterans Affairs and remains on track to achieve FedRAMP certification in the third quarter of 2026.

•Medical Education Expansion: Closed four additional medical education partners in the quarter, including entering a long-term strategic partnership with VCOM to support and gain insights following physicians from medical school to residency and clinical practice.

•Butterfly Garden™: Added a new partner focused on precision needle-guidance AI and expect three existing partner tools to become commercially available by year-end.

•Home & Community Care: Prepared for first commercial implementation in the second half of 2026, with revenue expected in the fourth quarter.

•International Expansion: Received regulatory authorization in Brazil, opening one of the world's largest and fastest-growing ultrasound markets.

Three Months Ended June 30, 2026 Financial Results

Revenue: Total revenue was $32.6 million, representing growth of 39% from $23.4 million in the second quarter of 2025. U.S. revenue was $27.6 million, up 57% from prior year, primarily driven by revenue from our Butterfly

Embedded™ partnerships, including our co-development partnership with Midjourney, as well as increased probe sales volume to our health system, medical school, and eCommerce customers. International revenue decreased 14% year-over-year to $5.0 million, largely resulting from decreased probe sales to our international distribution partners during the second quarter, although this decrease was partially offset by our recent commercial expansion into the Brazilian medical device market.

Gross margin: Gross profit was $23.3 million versus gross profit of $14.9 million in the prior year period. Gross margin increased to 71.4% compared to 63.7% in the prior year period. This increase was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as a reduction in software amortization costs for our historic software development investments.

Operating expenses: Operating expenses were $37.0 million, up 19% from $31.0 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $26.3 million, compared to $23.1 million in the second quarter of 2025, largely reflecting increased headcount in the current year from investments we've made in our internal capabilities throughout the past 12 months to support revenue growth as well as our product and software development projects.

Net loss: Net loss was $12.9 million, compared to $13.8 million in the prior year period.

Adjusted EBITDA: Adjusted EBITDA loss was $1.4 million, an

2026
Q1

Q1 2026 Earnings

8-K

Apr 30, 2026

0001804176-26-000014

EX-99.1

2 bfly-20260430xexx991.htm

EX-99.1

Document

Exhibit 99.1

Butterfly Network Reports First Quarter 2026 Financial Results

Delivered Revenue Above Consensus and Beat Adjusted EBITDA Guidance

•Reaffirmed full year Revenue and Adjusted EBITDA Guidance

•Delivered quarterly Revenue of $26.5 million in Q1, representing 25% YoY growth.

•Delivered 69% Gross Margin up 600 bps and Adjusted EBITDA of ($6.1M) up 32% YoY

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE) -- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “Butterfly opened the year with another strong quarter, coming in above consensus with 25% revenue growth and continued gross margin improvement. We are executing with discipline while continuing to invest in the vast opportunity ahead.”

DeVivo continued, “Our business is starting to come together around three growth engines. Point-of-care ultrasound is scaling globally. Home & Community Care is extending that capability into the patient environment. And Butterfly Embedded is expanding our technology beyond medical ultrasound into new modalities. These are not separate opportunities. They are all part of the same Butterfly platform, a single system that is beginning to work together and compound over time. We are still early, but the direction is clear, and we are building with focus and discipline to drive long-term growth.”

Recent Operational and Strategic Highlights:

•Gestational Age AI Tool: Received FDA clearance and initiated rollout of blind-sweep AI tool for rapid fetal age estimation across U.S. and global health markets.

•Butterfly Garden Ecosystem: Added two new partners, bringing the portfolio total to 30, while continuing to progress toward additional commercial-ready applications.

•Compass AI™ and Enterprise Momentum: Closed first enterprise deal of the year and drove significant growth in the software pipeline since launching the next generation Compass AI solution.

•Global Market Expansion: Advancing entry into new markets across the Americas and Asia, including high-growth regions such as Brazil, with iQ3 expansion in multiple countries.

•Home & Community Care: Progressing toward first commercial agreement in the first half of 2026, with initial statewide deployment expected in the third quarter.

•Butterfly Embedded™: Signed ninth company to the portfolio as of April 2026 and made meaningful development progress with existing partners.

•Apollo Platform Development: Continued advancement of next-generation semiconductor architecture designed to significantly increase data processing and compute performance.

Three Months Ended March 31, 2026 Financial Results

Revenue: Total revenue was $26.5 million, representing growth of 25% from $21.2 million in the first quarter of 2025. U.S. revenue was $21.4 million, up 25% from prior year, primarily driven by revenue from our Butterfly Embedded™ partnerships, including our co-development partnership with Midjourney. International revenue increased 23% year-over-year to $5.2 million, largely resulting from increased probe sales in the current year to

our distribution partners. Both our U.S. and international revenue also benefited from favorable shifts in our product sales mix towards our higher-priced iQ3 probes.

Gross margin: Gross profit was $18.3 million versus gross profit of $13.4 million in the prior year period. Gross margin increased to 68.9% compared to 63.0% in the prior year period. This increase was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as a reduction in software amortization costs for our historic software development investments.

Operating expenses: Operating expenses were $32.2 million, up 1% from $31.8 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $26.2 million, compared to $24.9 million in the first quarter of 2025, largely reflecting increased headcount in the current year from investments we've made in our internal capabilities throughout the past 12 months to support revenue growth as well as higher professional services costs.

Net loss: Net loss was $12.7 million, compared to $14.0 million in the prior year period.

Adjusted EBITDA: Adjusted EBITDA loss was $6.1 million, compared to $9.1 million in the prior year period.

EPS: EPS was $(0.05), compared to $(0.06) in the prior year period.

Adjusted EPS: Adjusted EPS was $(0.03), compared to $(0.04) in the prior year period.

Cash and cash equivalents: Cash and cash equivalents were $138.0 million as of March 31, 2026.

Guidance

Reaffirmed revenue guidance and

About Butterfly Network Inc. (BFLY) Earnings

This page provides Butterfly Network Inc. (BFLY) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on BFLY's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: